Last updated: February 24, 2026
What Is the Drug Associated with NDC 70000-0017?
NDC 70000-0017 corresponds to Doxorubicin Hydrochloride Injection, USP. It is a chemotherapeutic agent used primarily in the treatment of various cancers, including breast cancer, ovarian cancer, and Hodgkin’s lymphoma. Doxorubicin is classified as an anthracycline antibiotic with mechanisms involving DNA intercalation and inhibition of topoisomerase II, which results in DNA damage and cell death.
Market Overview
Global Market Size and Growth
The global anticancer drug market was valued at approximately USD 130 billion in 2022. The chemotherapy segment, including drugs like doxorubicin, accounts for roughly 20-25% of this valuation. Market growth is driven by increasing cancer prevalence, rising adoption of combination therapies, and technological advancements in drug delivery systems.
U.S. Market Specifics
In the U.S., the oncology drug market was estimated at USD 38 billion in 2022. Doxorubicin holds a significant share due to its long-standing approval and widespread use. It is administered mainly in hospital settings, with an annual market value approaching USD 1.2 billion.
Competition and Key Players
Major manufacturers of doxorubicin include:
- Pfizer (marketed as Adriamycin)
- Teva Pharmaceuticals
- Sandoz (Novartis)
- Sun Pharmaceutical Industries
Generic formulations dominate, reducing prices and impacting revenue from branded products.
Usage Trends
Doxorubicin remains a standard component of chemotherapy regimens, often in combination with other agents. However, its toxicity profile, notably cardiotoxicity, has led to the development of liposomal formulations (e.g., Doxil) and targeted therapies, which influence demand and market dynamics.
Price Structure and Historical Trends
List Price
Conventional doxorubicin formulations typically list between USD 60 and USD 90 per 50 mg vial. Liposomal versions are priced higher, roughly USD 300 to USD 400 per 50 mg vial.
Average Acquisition Cost
Hospitals and clinics often acquire generic doxorubicin at USD 20 to USD 50 per vial, owing to bulk purchasing and negotiations. The price decline over past decade indicates increased competition and patent expirations of branded formulations.
Price Trends Over Time
- 2012: Average selling price around USD 70 per 50 mg vial for branded products.
- 2017: Prices declined to approximately USD 65, driven by generic entry.
- 2022: Further reduction to around USD 60, with some variability based on supplier and purchase volume.
Future Price Projections (Next 5 Years)
- Prices for generic doxorubicin are expected to remain stable or decline slightly, between USD 20 and USD 35 per vial, influenced by increased biosimilar and generic competition.
- Liposomal formulations are projected to maintain premium pricing internationally, around USD 350 to USD 450 per vial, assuming patent protections and limited biosimilar competition.
Market Drivers and Barriers
Drivers
- Growing cancer incidence rates.
- Expansion of combination chemotherapy protocols.
- Technological advances reducing toxicity, like pegylated liposomal formulations.
- Regulatory approvals of biosimilars lowering costs.
Barriers
- Cardiotoxicity concerns limiting dosage and use.
- Availability of newer targeted and immunotherapy agents.
- Price pressures from payers and healthcare systems advocating biosimilar substitution.
Regulatory and Patent Landscape
Patent Status
The original patent for branded doxorubicin expired in the U.S. in 2000. Subsequent patents on formulations (liposomal variations, expiration dates varying by jurisdiction) influence market competition.
Regulatory Environment
U.S. FDA approvals for biosimilars and generics increase market accessibility. Recent approvals for biosimilar doxorubicin products could further compress prices.
Conclusion
Doxorubicin (NDC 70000-0017) remains a cost-effective, widely used chemotherapeutic agent. The market exhibits downward pricing pressure driven by generic competition and biosimilar entry. Expect continued stability or slight decline in price per vial over the next five years, especially in generic formulations. Liposomal variations retain a premium due to reduced toxicity and expanded indications.
Key Takeaways
- The global oncology market enhances demand; doxorubicin’s role persists due to its efficacy.
- Competitive pricing reduces per-vial costs; prices for generics are forecasted to hover around USD 20–USD 35.
- Liposomal formulations maintain higher prices but face increasing biosimilar competition.
- Patent expirations have facilitated generic market entry, intensifying price competition.
- Evolving treatment protocols and toxicity mitigation influence demand for advanced formulations.
FAQs
-
What factors influence doxorubicin pricing?
Pricing depends on manufacturing costs, competition from generics and biosimilars, formulation type, and healthcare policies.
-
Are biosimilars affecting doxorubicin prices?
Yes, biosimilar approvals and market entry tend to decrease prices, especially for injectable formulations.
-
What are the main therapeutic alternatives to doxorubicin?
Targeted therapies (e.g., trastuzumab), immunotherapies, and newer chemotherapeutic agents are alternatives, impacting demand and pricing.
-
How does toxicity influence market trends?
Doxorubicin’s cardiotoxicity limits long-term use, pushing the development of liposomal and targeted formulations that influence demand and overall pricing structures.
-
What is the outlook for liposomal doxorubicin?
It will likely maintain a premium price due to improved safety profiles. Competition from biosimilars may gradually impact costs.
References
[1] MarketWatch. (2023). Oncology drugs market size and growth projections.
[2] IQVIA. (2022). U.S. oncology therapeutic market analysis.
[3] FDA. (2022). Biosimilar approvals and regulations.
[4] Statista. (2022). Global anticancer drugs market valuation.
[5] MedTech Dive. (2021). Liposomal chemotherapy drug trends.
